Funds and ETFs Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 17/06/2024 BST 5-day change 1st Jan Change
157.3 USD -1.93% Intraday chart for Alnylam Pharmaceuticals, Inc. +2.50% -17.82%

ETFs positioned on Alnylam Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
5.08% 1 M€ +0.84% -
4.04% 2 M€ -.--%
2.78% 0 M€ 0.00% -
2.56% 0 M€ 0.00% -
1.78% 7 M€ +4.47%
1.39% 7 M€ -.--% -
1.20% 4 M€ +20.15%
1.19% 9 M€ +15.45% -
0.78% 15 M€ -3.51%
0.77% 2 M€ +9.20%
0.57% 21 M€ +8.51% -
0.25% 36 M€ +22.19%
0.21% 9 M€ -.--% -
0.13% 330 M€ -.--% -
0.13% 219 M€ +17.17% -
0.13% 1,448 M€ -.--% -
0.10% 9 M€ +9.43% -
0.10% 825 M€ +13.88%
0.09% 276 M€ +11.40% -
0.08% 1 M€ +0.04%
0.07% 35 M€ +17.03% -
0.05% 0 M€ 0.00% -
0.05% 2,567 M€ +18.13% -
0.05% 284 M€ -.--%
0.04% 26 M€ +16.85% -
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
160.4 USD
Average target price
217.9 USD
Spread / Average Target
+35.88%
Consensus
  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. Funds and ETFs Alnylam Pharmaceuticals, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW